Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Jgilbert who wrote (2760)	5/22/1998 3:43:00 PM
From: Anthony Wong	Respond to of 9523

Jgilbert, read my post #2761. I read your post after I've posted it, and my aspirin remark wasn't in response to yours. It really happened to me.

To: Jgilbert who wrote (2760)	5/22/1998 3:46:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Investors' reaction - excerpt from an updated Bloomberg report: Investors said they remain confident about the drug's safety and future prospects. Martin Bukoll, an analyst with Northern Trust Co., which held 8.7 million Pfizer shares as of December, said he's advising Northern Trust Fund managers to keep buying Pfizer at current price levels. ''Given the extensive clinical testing that Viagra underwent, in the absence of new compelling data, we believe that the drug is safe and efficacious for most patients when used as directed,'' Bukoll said. Pfizer is a ''stock we're probably going to stick with,'' added Mark Molnar, an analyst with the Ohio Public Employees Retirement System, which holds about 1.7 million Pfizer shares, according to regulatory filings. ''Short term, it may cause doctors not to write so many prescriptions,'' Molnar said. ''I don't think it will affect sales of the drug long-term.'' The 1,500 Pfizer salespeople pitching Viagra to doctors are supposed to tell them to check patients' cardiovascular history, McCormick said. Doctors also should review with patients the possible risks of resuming intercourse after a long interval ''between episodes,'' he said.